Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) emerging as key players in medical consultations and digital health solutions [1][2] Stock Performance & Valuation - HIMS has outperformed AMWL over the past three months, with a 35.1% increase compared to AMWL's 22.3% decline. In the past year, HIMS has rallied 183%, while AMWL has seen a decline of 20.3% [3] - HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 4.6X, above its three-year median of 2.3X. In contrast, AMWL's forward sales multiple is at 0.4X, below its median of 1.3X [4] Growth Potential for Hims & Hers - HIMS is expanding into new conditions treatable via telehealth, focusing on areas like sleep disorders and hypertension, which align with its business model [7] - HIMS has partnered with Novo Nordisk to enhance accessibility to obesity care, launching a six-month Wegovy access plan at $549/month [8] - Over 65% of new subscribers in 2024 benefited from personalized products, aided by the MedMatch AI tool for customized treatment plans [9] Growth Potential for Amwell - Amwell's platform allows clients to utilize their provider networks for virtual care across various modalities, from primary to specialty care [10] - The Converge platform enables care across in-person, virtual, and automated modalities, supporting interoperability with EHRs [11] - Amwell has a nationwide clinical coverage with around 1,000 active behavioral health providers and partnerships with organizations like the Cleveland Clinic [12] Earnings Projections - The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 166.7% improvement from 2024 [13] - The Zacks Consensus Estimate for AMWL's 2025 loss per share implies a 49.7% improvement from 2024 [15] Price Targets - The average price target for HIMS is $43.00, indicating a potential decline of 17.9% from the last close [17] - The average price target for AMWL is $10.00, suggesting a potential increase of 44.7% from the last close [18] Investment Recommendation - HIMS is viewed as a more stable and financially sound investment opportunity, with strong profitability and user engagement, generating substantial free cash flow [21] - AMWL is recognized for its rapid growth and expansion but is considered a lower-ranked investment option compared to HIMS [22]

Company Overview - Hims & Hers Health is a telehealth firm that provides direct access to medical consultations and prescription drugs for various cases [1] Analyst Insights - Daniel Sereda is the chief investment analyst at a family office, focusing on navigating diverse asset classes and filtering critical investment data [1] - The investing group Beyond the Wall Investing offers insights similar to those prioritized by institutional market participants [1]

Core Viewpoint - Hims & Hers Health, Inc. has introduced a new affordable pricing model for six months of prescription-only Wegovy, aiming to enhance accessibility to obesity care for Americans, which is expected to significantly boost the company's business [1][7]. Company Developments - Following the announcement of the new pricing model, Hims & Hers shares experienced a decline of nearly 8% [2]. - The company currently has a market capitalization of $11.94 billion and reported an earnings yield of 1.4%, which is favorable compared to the industry's negative yield. In the last quarter, Hims & Hers achieved an earnings surprise of 66.7% [3]. - Effective May 22, 2025, new customers can access Wegovy for $549 per month for six months, which includes a holistic approach to weight loss powered by technology [4]. - Hims & Hers plans to continue offering a wide range of weight loss treatment options, including other medications and clinically-backed care plans [5]. - The company recently reported strong improvements in both top and bottom lines for the first quarter of 2025, with an increase in subscribers and monthly online revenue per average subscriber [8]. Industry Prospects - The global weight management market was valued at $329.83 billion in 2024 and is projected to reach $488.42 billion by 2032, growing at a CAGR of approximately 5%. This growth is driven by rising obesity rates and the adoption of personalized healthcare solutions [6]. - The latest product availability is seen as a significant milestone for Hims & Hers, expected to enhance its business prospects [7].

Group 1 - Morgan Stanley has assigned a "hold" rating to Hims & Hers (HIMS.US) with a target price of $40, indicating a cautious outlook on the company's strategy in the competitive landscape of GLP-1 drugs [1] - Hims & Hers has only reduced the price of Wegovy by 8%, while competitors have slashed prices by 50%-62%, suggesting a less aggressive pricing strategy [1][2] - The company aims to provide a comprehensive weight loss solution, with a long-term vision of achieving a monthly profit of $100, which may include prescription services and patient support tools [3] Group 2 - New low-cost competitors such as LifeMD and Evernorth are emerging, offering Wegovy at significantly lower prices, which could pressure Hims & Hers' market position [2][3] - LifeMD is promoting Wegovy at $299/month, while Ro has set a promotional price of $244/month, both undercutting Hims & Hers' pricing [2] - The introduction of these low-cost products follows the May 22 deadline for the distribution of semaglutide injection products, indicating a shift in the competitive dynamics of the market [3]

Core Insights - Louis Stevens is a highly regarded investment analyst with a background as a former U.S. Army engineer officer, holding an MBA and a BA in political science [1] - He has established L.A. Stevens Research, where he manages the LAS Index, a stock basket that has consistently outperformed market indices since its inception [2] Company Overview - L.A. Stevens Research utilizes a proprietary method for selecting stocks, contributing to its strong performance in the investment community [2] - The LAS Index is designed to cater to a diverse audience, including beginners, busy professionals, and experienced fund managers [2]

Core Viewpoint - The interconnectedness of today's stock market presents both increased investment opportunities and greater risks, particularly highlighted by the recent decline of UnitedHealth Group, which fell 30.6% in a month, affecting smaller companies like Hims & Hers Health [2][3]. Company Overview - Hims & Hers Health Inc. is currently trading at $55.93, down 3.56%, with a 52-week range of $13.47 to $72.98 and a P/E ratio of 126.73. The price target is set at $37.67 [4]. - The stock has shown resilience, trading at 85% of its 52-week high, indicating potential for a new bull run [5]. Recent Performance - Hims & Hers experienced a 124.6% rally over the past month, raising questions about the sustainability of this growth and whether the company's fundamentals have been fully priced in [6]. - The company reported a 38% annual growth in subscribers, reaching 2.4 million users, which reflects consumer trust in its innovative business model [9]. Financial Metrics - Hims & Hers generated $586 million in revenue this quarter, marking a significant 111% growth compared to the same quarter last year. This growth is supported by a mix of technology that allows for higher margins and stable free cash flow [10]. - Free cash flow is crucial for future growth and investor returns, contributing to the excitement surrounding Hims & Hers stock [11]. Institutional Activity - Institutional investors have shown mixed activity, with Northern Trust increasing its holdings by 19.5% to $71.9 million, while Vanguard decreased its position by 8.8%. This rebalancing is seen as a healthy sign for the stock's future [12][13]. Market Sentiment - Despite recent volatility in the medical sector, driven by UnitedHealth's decline, the fundamental aspects of Hims & Hers suggest a positive outlook for the stock [14]. - Hims & Hers Health currently holds a "Hold" rating among analysts, with some top-rated analysts identifying other stocks as better buys at this time [15].

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Company Overview - DBV Technologies S.A. (DBVT) is a notable stock within the Medical sector, which consists of 999 companies and currently ranks 4 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 506 stocks and is ranked 70 in the Zacks Industry Rank [6] Performance Metrics - DBVT has experienced a year-to-date gain of approximately 210.7%, significantly outperforming the average loss of 4.4% in the Medical sector [4] - The Zacks Consensus Estimate for DBVT's full-year earnings has increased by 78.9% over the past quarter, indicating a positive shift in analyst sentiment [4] Comparison with Peers - Hims & Hers Health, Inc. (HIMS) is another Medical stock that has shown strong performance, with a year-to-date return of 153.1% and a Zacks Rank of 2 (Buy) [5] - The Medical Info Systems industry, to which HIMS belongs, has seen a year-to-date increase of 16.9%, contrasting with the performance of DBVT's industry [7]

When I wrote about Hims & Hers (NYSE: HIMS ) for the first time in February, the stock had already appreciated significantly, reaching $44. I believed continued growth lay ahead and rated it a buy.I analyze securities based on value investing, an owner's mindset, and a long-term horizon. I don't write sell articles as those are considered short theses, and I never recommend shorting.Former advisory representative at Fidelity. I do my own investing now and share my research here.Analyst’s Disclosure: I/we ha ...

Hims and Hers, Inc. NYSE: HIMS shows strongly bullish signs that begin and end with the stock price action. It reflects volatility, but the bias is upward with rising support and the most recent swing, a bullish rebound, looks very strong within the pattern. Hims & Hers Health TodayHIMSHims & Hers Health$61.95 -0.39 (-0.63%) 52-Week Range$13.47▼$72.98P/E Ratio141.24Price Target$37.67Add to WatchlistIt consists of Three White Soldiers or Three Green Soldiers, technically, a bullish pattern formed by three c ...